Detection of activity of P‐glycoprotein in human tumour samples using rhodamine 123
- 1 September 1992
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 82 (1) , 161-168
- https://doi.org/10.1111/j.1365-2141.1992.tb04608.x
Abstract
Summary Based on the fluorescent properties of the dye rhodamine 123 (Rh123), which is transported by the membrane efflux pump P-glycoprotein (P-gp), we developed a functional flow cytometric assay for the detection of multidrug-resistant (MDR) cells. Using drug sensitive cell lines (KB-3–1) and MDR mutants (KB-8–5, KB-C1) experimental conditions were established that enabled demonstration of significant differences in Rhl23 efflux and accumulation. Subsequently we investigated the applicability of this functional assay for the prediction of MDR in human peripheral blood and bone marrow samples. Using two-colour flow cytometry, the leukaemic blast cells of six patients suffering from acute myeloid leukaemia (AML) were analysed. In three cases the blast cells showed a rapid and marked Rh123 efflux. In the presence of MDR inhibitors these cells retained Rh123. To determine whether the efflux of Rhl23 was associated with P-gp expression, the leukaemic cells were stained with the monoclonal antibody MRK-16. In addition extracted RNA was analysed by polymerase chain reaction to evaluate the expression of mdr 1 mRNA. In all three Rh123+ cases mdr 1 mRNA was detectable whereas only one AML case expressed P-gp. In comparing Rh123 with daunorubicin, which also allows the detection of MDR cells, accumulation studies proved Rh123 to be the more sensitive drug for flow cytometric MDR screening. Additionally, two-colour flow cytometry was much easier to perform with Rh123 than with daunorubicin. Our results indicate that flow cytometric measurement of Rh123 accumulation/efflux proves applicable to detect MDR cells in heterogenous clinical samples.Keywords
This publication has 32 references indexed in Scilit:
- Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipineZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Multidrug resistance from the clinical point of viewEuropean Journal of Cancer and Clinical Oncology, 1991
- Multidrug resistance activity in human lymphocytesHuman Immunology, 1991
- B-859-35, a new drug with anti-tumor activity reverses multi-drug resistanceInternational Journal of Cancer, 1991
- Rapid Functional Assay for Multidrug Resistance in Human Tumor Cell Lines Using the Fluorescent Indicator Fluo-3JNCI Journal of the National Cancer Institute, 1991
- Expression of the multiple drug resistance gene (mdr‐1) and epitope masking in chronic lymphatic leukaemiaBritish Journal of Haematology, 1990
- Expression of mdr1 and mdr3 Multidrug-resistance Genes in Human Acute and Chronic Leukemias and Association With Stimulation of Drug Accumulation by CyclosporineJNCI Journal of the National Cancer Institute, 1990
- Multidrug Resistance: Molecular Biology Clinical RelevanceJNCI Journal of the National Cancer Institute, 1989
- Multidrug Resistance: P-glycoprotein and Its Allies--The Elusive FoesJNCI Journal of the National Cancer Institute, 1989
- Multiple-Drug Resistance in Human CancerNew England Journal of Medicine, 1987